Quantum BioPharma is trading at $2.83, down 8.40%, in pre-market, with no clearly identified overnight catalyst for the October 7 decline.
- On October 6, the company announced that Thermo Fisher’s clinical research business would support start-up of its Phase 2 Lucid-MS trial; this preceded the decline and does not establish its cause.
- The prior session also saw consecutive declines.
- Supplied pre-market index readings are mixed and show no broad-market move exceeding 0.5% in the same direction.